Announcements Trials
Browse Landscape

Phase

Phase 2 4Phase NA 3Phase 1 2Phase 3 1Phase 1/2 1

Status

Withdrawn 2

Sponsor Class

OTHER 2

Study Type

Interventional 2

Sponsor

Cancer Type

Gastrointestinal 2

Conditions

Glioblastoma 60Carcinoma, Non-Small-Cell Lung 48Lung Neoplasms 39Head and Neck Neoplasms 26Gliosarcoma 26Squamous Cell Carcinoma of Head and Neck 25Pancreatic Neoplasms 25Central Nervous System Neoplasms 23Brain Neoplasms 22Rectal Neoplasms 21Breast Neoplasms 17Astrocytoma 17Sarcoma 16Neoplasms 16Glioma 15Uterine Cervical Neoplasms 14Prostatic Neoplasms 14Esophageal Neoplasms 14Carcinoma, Squamous Cell 11Lymphoma, Follicular 10Leukemia 10Melanoma 9Lymphoma, Large B-Cell, Diffuse 9Lymphoma 9Leukemia, Lymphocytic, Chronic, B-Cell 9Precursor Cell Lymphoblastic Leukemia-Lymphoma 8Lymphoma, Non-Hodgkin 8Neoplasm Metastasis 7Myelodysplastic Syndromes 7Lymphoma, Mantle-Cell 7

Interventions

Sorafenib 20Bevacizumab 7pembrolizumab 5Oxaliplatin 5Melphalan 5Leucovorin 5Irinotecan 5Nivolumab 4Ipilimumab 4Fluorouracil 4Cyclophosphamide 4Capecitabine 4fludarabine 3Sirolimus 3Radiosurgery 3Gemcitabine 3Filgrastim 3Carboplatin 3toripalimab 2spartalizumab 2regorafenib 2pazopanib 2lenvatinib 2ixabepilone 2durvalumab 2atezolizumab 2Vorinostat 2Thiotepa 2Temozolomide 2Sirtuins 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Phase 1 × Liver Neoplasms × Radiotherapy × Clear all
NCT02989870 2020-06-05

Sorafenib and Bavituximab Plus SBRT in Unresectable Hepatocellular Carcinoma

H. Lee Moffitt Cancer Center and Research Institute

Phase 1 Withdrawn
Gastrointestinal

Carcinoma, Hepatocellular, Liver Diseases, Liver Neoplasms

NCT01618253 2013-09-05

Radiation Therapy With Sorafenib for TACE-Resistant Hepatocellular Carcinoma

Medical College of Wisconsin

Phase 1 Withdrawn
Gastrointestinal

Carcinoma, Hepatocellular, Liver Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡